$165.96
-1.59 (-0.95%)
At Close: May 23, 2025
Balchem Earnings Calls
Q1 2025
Missed
$1.22 (-2.40%)
Release date | Apr 24, 2025 |
EPS estimate | $1.25 |
EPS actual | $1.22 |
EPS Surprise | -2.40% |
Revenue estimate | 245.699M |
Revenue actual | 250.519M |
Revenue Surprise | 1.96% |
Q4 2024
Missed
$1.03 (-7.21%)
Release date | Feb 21, 2025 |
EPS estimate | $1.11 |
EPS actual | $1.03 |
EPS Surprise | -7.21% |
Revenue estimate | 244.913M |
Revenue actual | 240.004M |
Revenue Surprise | -2.00% |
Q3 2024
Beat
$1.13 (1.80%)
Release date | Oct 25, 2024 |
EPS estimate | $1.11 |
EPS actual | $1.13 |
EPS Surprise | 1.80% |
Revenue estimate | 235.08M |
Revenue actual | 239.94M |
Revenue Surprise | 2.07% |
Q2 2024
Beat
$1.09 (5.83%)
Release date | Jul 26, 2024 |
EPS estimate | $1.03 |
EPS actual | $1.09 |
EPS Surprise | 5.83% |
Revenue estimate | 239.69M |
Revenue actual | 234.081M |
Revenue Surprise | -2.34% |
Last 4 Quarters for Balchem
Below you can see how BCPC performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q2 2024
Beat
Release date | Jul 26, 2024 |
Fiscal end date | Jun 30, 2024 |
Price on release | $180.78 |
EPS estimate | $1.03 |
EPS actual | $1.09 |
EPS surprise | 5.83% |
Date | Price |
---|---|
Jul 22, 2024 | $175.64 |
Jul 23, 2024 | $179.69 |
Jul 24, 2024 | $174.95 |
Jul 25, 2024 | $174.81 |
Jul 26, 2024 | $180.78 |
Jul 29, 2024 | $181.56 |
Jul 30, 2024 | $178.16 |
Jul 31, 2024 | $177.46 |
Aug 01, 2024 | $175.99 |
4 days before | 2.93% |
4 days after | -2.65% |
On release day | 0.431% |
Change in period | 0.199% |
Q3 2024
Beat
Release date | Oct 25, 2024 |
Fiscal end date | Sep 30, 2024 |
Price on release | $171.46 |
EPS estimate | $1.11 |
EPS actual | $1.13 |
EPS surprise | 1.80% |
Date | Price |
---|---|
Oct 21, 2024 | $167.78 |
Oct 22, 2024 | $167.61 |
Oct 23, 2024 | $166.76 |
Oct 24, 2024 | $166.16 |
Oct 25, 2024 | $171.46 |
Oct 28, 2024 | $170.79 |
Oct 29, 2024 | $169.26 |
Oct 30, 2024 | $168.88 |
Oct 31, 2024 | $167.33 |
4 days before | 2.19% |
4 days after | -2.41% |
On release day | -0.391% |
Change in period | -0.268% |
Q4 2024
Missed
Release date | Feb 21, 2025 |
Fiscal end date | Dec 31, 2024 |
Price on release | $163.73 |
EPS estimate | $1.11 |
EPS actual | $1.03 |
EPS surprise | -7.21% |
Date | Price |
---|---|
Feb 14, 2025 | $164.82 |
Feb 18, 2025 | $166.01 |
Feb 19, 2025 | $163.78 |
Feb 20, 2025 | $161.34 |
Feb 21, 2025 | $163.73 |
Feb 24, 2025 | $165.57 |
Feb 25, 2025 | $173.59 |
Feb 26, 2025 | $172.69 |
Feb 27, 2025 | $172.00 |
4 days before | -0.661% |
4 days after | 5.05% |
On release day | 1.12% |
Change in period | 4.36% |
Q1 2025
Missed
Release date | Apr 24, 2025 |
Fiscal end date | Mar 31, 2025 |
Price on release | $154.20 |
EPS estimate | $1.25 |
EPS actual | $1.22 |
EPS surprise | -2.40% |
Date | Price |
---|---|
Apr 17, 2025 | $161.50 |
Apr 21, 2025 | $156.92 |
Apr 22, 2025 | $157.50 |
Apr 23, 2025 | $158.31 |
Apr 24, 2025 | $154.20 |
Apr 25, 2025 | $153.64 |
Apr 28, 2025 | $156.09 |
Apr 29, 2025 | $156.01 |
Apr 30, 2025 | $156.55 |
4 days before | -4.52% |
4 days after | 1.52% |
On release day | -0.363% |
Change in period | -3.07% |
Balchem Earnings Call Transcript Summary of Q1 2025
Key Points Summary from Balchem's Q1 2025 Earnings Call for Investors:
- Record Financial Performance:
- Consolidated Sales: Achieved $251 million, up 4.5% year-over-year.
- Record Adjusted EBITDA: Reported at $66 million, an 8.9% increase from the prior year, with an adjusted EBITDA margin of 26.5%.
- Net Income: Reached $37 million, a 27.8% increase, resulting in diluted earnings per share of $1.13.
- Adjusted Net Earnings: Set at $40 million (up 19.2%), translating to $1.22 per diluted share.
- Strong Segment Performance:
- Human Nutrition & Health: Sales grew to $158 million (up 3.7%), with earnings from operations of $38 million (up 14.2%).
- Animal Nutrition & Health: Sales increased to $57 million (up 6.2%), with earnings from operations surging 154.2% to $5 million.
- Specialty Products: Delivered $33 million in sales (up 5.3%), and earnings from operations rose to $10 million (up 16.9%).
- Market Conditions:
- Balchem is well-positioned in the evolving global trade environment, with minimal reliance on imports from China, and strong cash flows and a solid balance sheet.
- Potential tariff impacts are being managed through supply chain flexibility and pricing actions, with approximately $100 million of raw materials imported into the U.S. annually.
- Outlook and Strategy:
- Strong demand and recovery in the Animal Nutrition & Health segment, especially with the successful launch of new products.
- Continued optimism for growth in the Human Nutrition & Health segment driven by strong consumer demand and successful new product introductions.
- Focus on maintaining growth while closely monitoring global economic conditions and potential impacts from ongoing trade disputes.
- Cash Management and Debt:
- Cash flow from operations was $36 million, with free cash flow of $31 million.
- Net debt stands at $140 million, with a leverage ratio at 0.5, showing strong financial health.
- Plans for capital allocation emphasize investing in organic growth, potential M&A opportunities, and addressing share dilution as needed.
- Risk Factors:
- Monitoring the effects of global demand fluctuations due to trade policies and recessionary concerns.
- Potential impacts from currency fluctuations, particularly with the euro affecting translational revenues.
- Patent and anti-dumping issues in Europe are being closely watched, with a case pending review by the EU.
- Future Engagements:
- Management will attend various industry conferences in June and July, which may provide further insights and engagement opportunities with investors.
Conclusion:
Balchem's first quarter performance indicates strong operational execution, resilience in market conditions, and strategic positioning against potential risks. The management team is confident in the company's growth trajectory for 2025, supported by solid fundamentals and proactive measures to address external challenges. Investors should monitor market trends, global trade dynamics, and upcoming earnings reports.
Balchem Earnings History
Earnings Calendar
FAQ
When is the earnings report for BCPC?
Balchem Corporation (BCPC) has scheduled its earnings report for Jul 25, 2025 before the markets open.
What is the BCPC price-to-earnings (P/E) ratio?
BCPC P/E ratio as of May 23, 2025 (TTM) is 39.43.
What is the BCPC EPS forecast?
The forecasted EPS (Earnings Per Share) for Balchem Corporation (BCPC) for the first fiscal quarter 2025 is $1.25.
What are Balchem Corporation's retained earnings?
On its balance sheet, Balchem Corporation reported retained earnings of $250.52 million for the latest quarter ending Mar 31, 2025.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.